135 related articles for article (PubMed ID: 19856097)
21. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
[TBL] [Abstract][Full Text] [Related]
22. Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families.
Pylkäs K; Erkko H; Nikkilä J; Sólyom S; Winqvist R
BMC Cancer; 2008 May; 8():146. PubMed ID: 18501021
[TBL] [Abstract][Full Text] [Related]
23. Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.
Guénard F; Labrie Y; Ouellette G; Joly Beauparlant C; Simard J; ; Durocher F
J Hum Genet; 2008; 53(7):579. PubMed ID: 18414782
[TBL] [Abstract][Full Text] [Related]
24. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.
Yurgelun MB; Kulke MH; Fuchs CS; Allen BA; Uno H; Hornick JL; Ukaegbu CI; Brais LK; McNamara PG; Mayer RJ; Schrag D; Meyerhardt JA; Ng K; Kidd J; Singh N; Hartman AR; Wenstrup RJ; Syngal S
J Clin Oncol; 2017 Apr; 35(10):1086-1095. PubMed ID: 28135145
[TBL] [Abstract][Full Text] [Related]
25. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
26. Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.
Kleibl Z; Kristensen VN
Breast; 2016 Aug; 28():136-44. PubMed ID: 27318168
[TBL] [Abstract][Full Text] [Related]
27. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
28. Radiotherapy in the treatment of hereditary breast cancer.
Pierce LJ; Haffty BG
Semin Radiat Oncol; 2011 Jan; 21(1):43-50. PubMed ID: 21134653
[TBL] [Abstract][Full Text] [Related]
29. Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing.
Yang X; Wu J; Lu J; Liu G; Di G; Chen C; Hou Y; Sun M; Yang W; Xu X; Zhao Y; Hu X; Li D; Cao Z; Zhou X; Huang X; Liu Z; Chen H; Gu Y; Chi Y; Yan X; Han Q; Shen Z; Shao Z; Hu Z
PLoS One; 2015; 10(4):e0125571. PubMed ID: 25927356
[TBL] [Abstract][Full Text] [Related]
30. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
Riedlova P; Janoutova J; Hermanova B
Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
[TBL] [Abstract][Full Text] [Related]
31. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
[TBL] [Abstract][Full Text] [Related]
32. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.
Seal S; Thompson D; Renwick A; Elliott A; Kelly P; Barfoot R; Chagtai T; Jayatilake H; Ahmed M; Spanova K; North B; McGuffog L; Evans DG; Eccles D; ; Easton DF; Stratton MR; Rahman N
Nat Genet; 2006 Nov; 38(11):1239-41. PubMed ID: 17033622
[TBL] [Abstract][Full Text] [Related]
33. Interaction between BRCA1/BRCA2 and ATM/ATR associate with breast cancer susceptibility in a Chinese Han population.
Wang K; Ye Y; Xu Z; Zhang X; Hou Z; Cui Y; Song Y
Cancer Genet Cytogenet; 2010 Jul; 200(1):40-6. PubMed ID: 20513533
[TBL] [Abstract][Full Text] [Related]
34. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
Alter BP; Best AF
Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
[TBL] [Abstract][Full Text] [Related]
35. BRIP1, a potential candidate gene in development of non-BRCA1/2 breast cancer.
Ouhtit A; Gupta I; Shaikh Z
Front Biosci (Elite Ed); 2016 Jan; 8(2):289-98. PubMed ID: 26709662
[TBL] [Abstract][Full Text] [Related]
36. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer.
Reid S; Schindler D; Hanenberg H; Barker K; Hanks S; Kalb R; Neveling K; Kelly P; Seal S; Freund M; Wurm M; Batish SD; Lach FP; Yetgin S; Neitzel H; Ariffin H; Tischkowitz M; Mathew CG; Auerbach AD; Rahman N
Nat Genet; 2007 Feb; 39(2):162-4. PubMed ID: 17200671
[TBL] [Abstract][Full Text] [Related]
37. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
[TBL] [Abstract][Full Text] [Related]
38. Current and future role of genetic screening in gynecologic malignancies.
Ring KL; Garcia C; Thomas MH; Modesitt SC
Am J Obstet Gynecol; 2017 Nov; 217(5):512-521. PubMed ID: 28411145
[TBL] [Abstract][Full Text] [Related]
39. Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk.
Baynes C; Healey CS; Pooley KA; Scollen S; Luben RN; Thompson DJ; Pharoah PD; Easton DF; Ponder BA; Dunning AM;
Breast Cancer Res; 2007; 9(2):R27. PubMed ID: 17428325
[TBL] [Abstract][Full Text] [Related]
40. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
